KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) FCF Margin: 2009-2025

Historic FCF Margin for Novavax (NVAX) over the last 17 years, with Sep 2025 value amounting to 150.16%.

  • Novavax's FCF Margin rose 32314.00% to 150.16% in Q3 2025 from the same period last year, while for Sep 2025 it was -38.37%, marking a year-over-year decrease of 2584.00%. This contributed to the annual value of -14.71% for FY2024, which is 6333.00% up from last year.
  • According to the latest figures from Q3 2025, Novavax's FCF Margin is 150.16%, which was up 305.71% from -73.00% recorded in Q2 2025.
  • In the past 5 years, Novavax's FCF Margin registered a high of 150.16% during Q3 2025, and its lowest value of -426.67% during Q1 2023.
  • Over the past 3 years, Novavax's median FCF Margin value was -63.71% (recorded in 2023), while the average stood at -82.45%.
  • As far as peak fluctuations go, Novavax's FCF Margin surged by 83,322bps in 2021, and later plummeted by 41,171bps in 2023.
  • Quarterly analysis of 5 years shows Novavax's FCF Margin stood at -160.12% in 2021, then soared by 12,071bps to -39.41% in 2022, then crashed by 2,431bps to -63.71% in 2023, then plummeted by 13,460bps to -198.31% in 2024, then spiked by 32,314bps to 150.16% in 2025.
  • Its FCF Margin stands at 150.16% for Q3 2025, versus -73.00% for Q2 2025 and -28.01% for Q1 2025.